APLM apollomicsinc.com Final Profit

Corporate emblem and logo of apollomicsinc.com (APLM)

Backed by patent protection and FDA/NMPA certification, Apollomics, Inc. (APLM) is successfully expanding its market presence. The company's net income dynamics, provided by GURU.Markets data, confirm the effectiveness of R&D investments in top-tier talent and the implementation of robotic data analysis to accelerate target discovery. The value has stabilized at -0.01, signaling the business's current fundamental resilience.

APLM (Apollomics Corp) Net Profit history from 02/21/2024 to 10/29/2026

Analytical breakdowns and data insights for company apollomicsinc.com (APLM)

- stock value and consensus price forecast:
Market Price Apollomics|APLM - Price Target Chart
- market capitalization data:
Market Value Apollomics, Inc.|APLM - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Apollomics|APLM - Book Capitalization|Market Cap to Net Assets Ratio apollomicsinc.com|APLM - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Apollomics, Inc.|APLM - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Apollomics|APLM - Company Aggregate Debts|Debts to Book Value Apollomics, Inc.|APLM - Company Long-Term Debts|Company Short-Term Debts Apollomics|Critical Liquidity Ratio apollomicsinc.com
- net income and valuation multiples indicators:
APLM - Company Net Income
Fundamental valuation:APLM Apollomics Corp
Manufactured product of Apollomics Inc.

This indicator determines the investment stability of the issuer by analyzing the company's final net income, adjusted for one-time speculative factors to identify real operational efficiency. Positive dynamics in the final net income of Apollomics, Inc. (APLM) confirm the financial viability of Apollomics, Inc., which is critically important for the commercialization of webreltinib and the expansion of solid tumor therapies in the US and Chinese markets.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Net Profit sellaslifesciences.com (SLS)|Company Net Income Actuate Therapeutics ACTU|CTOR (Citius Oncology Inc.) - Profit After Tax|HURA - Company Net Income|Company Net Income Protara Tx|Fate Therapeutics, Inc. (FATE) - Company Net Income|WHWK (Aadi Bioscience) - Company Net Income|Company Net Income TScan Therapeutics Inc|Company Net Income CSBR|Company Net Income XBiotech Inc. (XBIT)|CVM - Company Net Income|Company Net Income OS Therapies Incorporated OSTX|RADX - Net Income|Artiva - Net Profit|Net Financial Result Adlai Nortye Ltd. ANL|VERU: Net Profit|Net Income Tempest Therapeutics Corp|Company Net Income Xilio Therapeutics Inc|Enochian BioSciences (RENB) - Net Financial Result|Net Income MURA (Mural Oncology plc)|KAPA (kairospharma.com) - Final Profit|Net Profit OKUR (OnKure Therapeutics)|Net Financial Result CytoMed Therapeutics Ltd (GDTC)|CRIS - Company Net Income|THAR (tharimmune.com) - Company Profit|ADVB: Net Profit|Net Income Genprex Inc.|Net Income CLDI|Sunshine Biopharma Inc. (SBFM) - Net Financial Result|Net Profit XBIO|Net Profit salariuspharma.com (SLRX)|Company Net Income Purple Biotech Ltd. PPBT|AONC (American Oncology Network Inc) - Profit After Tax|BGNE - Company Net Income|CKPT: Company Net Income|Elevation Oncology, Inc. (ELEV) - Company Net Income|Net Income iCAD|IKNA (Ikena Oncology Inc.) - Net Profit|Net Income Notable Labs Ltd (NTBL)|Net Profit VIRX|Net Profit MorphoSys Corporation (MOR)|Company Net Income NAYA Biosciences NAYA|AAPGV: Company Profit